Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $384.9M
!
Reach your audience today.

Corporate Spotlight
Last update - 16.12pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 8.4¢ | Day High | 9.8¢ | Day Low | 8.3¢ | |||
| Daily Volume | 37111380 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 9.0¢ | 29875 | 0 | 9.2¢ | 3000 | |
Directors & Senior Management
| Mr. Adolfo Sachsida | Advisor to the Board |
| Mr. Adriano Rios | Director of Mining Operations – Brazil |
| Mr. Caue Pauli De Araujo | Director of Corporate Development |
| Mr. John Dawson | Non-Executive Director |
| Mr. John Prineas | Executive Chairman of the Board |
| Mr. John Prineas | Executive Chairman |
| Ms. Sarah Shipway | Company Secretary & Independent Non-Executive Director |
| Mr. Thiago Amaral | Director of ESG & Technical Development - Brazil |
| Mr. Wanderly Basso | Group Exploration Manager |
Data source: ADVFN
